Cancer clinical trials are strengthening Ireland’s pharmaceutical research ecosystem, with new figures highlighting the financial contribution of industry-sponsored studies alongside their role in bringing emerging treatments closer to patients. Cancer Trials Ireland estimates that clinical trials generated €23.77 million in combined healthcare savings, pharmaceutical investment and potential hospital revenue over the 12 months to August 2026.

The findings, reported by RTÉ News, are drawn from the charity’s Value of Cancer Trials 2 report. Its analysis estimates that 38 investigational medicine trials involving 230 patients avoided €6.51 million in standard-of-care drug costs between September 2025 and August 2026. Where trial sponsors cover treatment costs, including medicines and relevant tests or procedures, these expenses do not need to be met by the patient, insurer or State.

The report identifies a further €6.76 million in estimated inward investment through investigational medicines supplied by pharmaceutical companies across 20 trials. It also estimates €10.5 million in potential hospital site-fee revenue, calculated using 423 patients recruited to drug trials and an assumed average sponsor payment of €25,000 per patient. Together, these three categories make up the €23.77 million estimate. The figure should be understood as a combined measure of different forms of value, not direct cash savings to the State.

The scale of activity provides further context. Cancer Trials Ireland reports that 3,938 patients participated in cancer trials during the 12-month period, with approximately 160 studies open across Ireland. The organisation supports clinical research through collaboration with hospitals, clinicians and research professionals. Its published report also records 73 industry-sponsored clinical trials commencing in Ireland in 2025, up 44% from 51 in 2024. This increase covers all disease areas rather than cancer trials alone.

For pharmaceutical sponsors, a capable clinical research environment can help connect investigational medicines with suitable patients, experienced clinical teams and hospital research infrastructure. The report also identifies opportunities to improve Ireland’s competitiveness: the country ranked 14th among 27 EU member states for industry-sponsored trials per capita in 2025. Cancer Trials Ireland has highlighted protected research time, workforce security and more efficient trial processes as areas requiring continued attention.

Public attitudes offer another encouraging signal. A national survey cited in the report found that 78% of respondents wanted more clinical trials in Ireland, while 69% said they would be willing to participate. Building on this support, alongside the growth in industry-sponsored activity, could help Ireland attract further research and strengthen collaboration between pharmaceutical companies and the health service.

For the sector, the lesson is direct: clinical trials create value across the pharmaceutical ecosystem, from investigational medicines and sponsor investment to hospital research activity and patient access. Continued support for clinical research can help Ireland turn this established capability into stronger international partnerships and future growth in life sciences.